aed peptide FAQ

Prioritise suppliers offering batch-specific certificates of analysis with HPLC and mass spectrometry data—generic product descriptions without verifiable purity documentation indicate unreliable synthesis controls. Our experience working with research teams sourcing peptides for musculoskeletal studies shows that requesting sample CoAs before placing bulk orders eliminates 70% of quality issues. Confirm the supplier operates under GMP or ISO standards, stores lyophilised peptides at −20°C, and ships with cold packs or dry ice to prevent temperature excursions during transit.

Peptides below 90% purity contain truncated sequences, deletion peptides, or residual synthesis reagents that can skew dosing calculations and introduce variability into experimental results. Contact the supplier for a replacement batch or adjust your dosing to account for the actual peptide content—if the CoA reports 85% purity, you'll need to increase the reconstituted volume proportionally to achieve the intended molar concentration. Purity below 80% should be rejected outright.

Verify the amino-acid sequence on the certificate of analysis—if it lists Ala-Glu-Asp or the molecular formula C₉H₁₅N₃O₇, the compound is structurally identical to Cartalax regardless of the label. Cross-reference the batch number with the CoA, confirm HPLC purity exceeds 95%, and proceed with your protocol as planned. The name difference reflects supplier nomenclature conventions, not a formulation change.

Search for the amino-acid sequence (Ala-Glu-Asp or AED) rather than the proprietary name—PubMed and Google Scholar index by molecular structure as well as trade names. Studies referencing Cartalax in Russian or Eastern European journals often describe the same protocols as AED studies published in Western research outlets. The experimental outcomes, dosing ranges, and tissue targets should align if the underlying peptide structure matches.

Switch to intranasal delivery or direct CNS injection. Both bypass the BBB and achieve therapeutic concentrations in brain parenchyma within 30 minutes. Intranasal administration delivers peptides to the brain via olfactory and trigeminal nerve pathways, with 5 to 20% of the administered dose reaching the CNS depending on peptide molecular weight and formulation. For spinal cord injury models, intrathecal injection via lumbar puncture provides direct access to cerebrospinal fluid and achieves uniform peptide distribution along the spinal cord within 1 to 2 hours. Systemic administration requires 10 to 50-fold higher doses to achieve equivalent CNS concentrations compared to direct delivery.

This dissociation between histology and function is common in neuroprotection research. Preserved axonal structure does not guarantee preserved functional connectivity. Verify that the lesion is anatomically positioned to affect the behavioral circuit being tested: if AED peptide preserves axons in the dorsolateral spinal cord but your behavioral test measures forelimb skilled reaching (which depends on dorsal corticospinal tract integrity), the mismatch explains the null result. Electrophysiological measures (motor evoked potentials, compound action potential recordings) often reveal functional preservation that behavioral tests miss, particularly when behavioral deficits are mild or compensatory mechanisms obscure recovery.

Measure peptide stability in CSF ex vivo before initiating in vivo studies. Collect CSF from the target species, spike it with AED peptide at the intended concentration, incubate at 37°C, and measure peptide concentration via HPLC or mass spectrometry at 1, 3, 6, 12, and 24 hours. If half-life is below 6 hours, consider using a protease-resistant analog (D-amino acid substitution at cleavage sites, cyclization, or PEGylation) or administering the peptide via continuous infusion rather than bolus injection. Many bioactive peptides degrade within 2 to 4 hours in CSF due to endogenous peptidase activity. Stability testing is non-negotiable for reproducible outcomes.

Administer the dose as planned and document the time interval from injury to administration. Delayed dosing may still provide modest axonal protection even if the primary excitotoxic prevention window has closed. The mechanism shifts: early administration prevents calcium influx and calpain activation, while delayed administration (6 to 24 hours) may still stabilize residual intact axons in the penumbra and reduce secondary injury from inflammation-driven calcium dysregulation. Preclinical data shows 15 to 25% reduction in axonal injury markers with delayed dosing, compared to 60 to 75% with early administration. Document neurological outcomes at multiple time points to capture delayed recovery patterns.